.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A recent case report in Postgraduate Medicine underscores severe ivermectin neurotoxicity risks. A 73-year-old woman with metastatic breast cancer self-administered massive doses of the antiparasitic agent. She acted on health misinformation found online. Consequently, she arrived at the hospital with acute mental status changes and life-threatening complications. This incident reflects a growing trend where patients bypass evidence-based care for unproven \"miracle cures.\"
The patient presented with generalized seizures and respiratory failure. These symptoms typically occur when high drug concentrations overwhelm the blood-brain barrier. Specifically, ivermectin is usually excluded from the central nervous system by P-glycoprotein. However, massive doses saturate this efflux pump. Therefore, the drug binds to GABA-gated chloride channels in the brain. This leads to profound depression of the central nervous system. Because the patient required immediate intervention, the medical team initiated mechanical ventilation and anticonvulsant therapy.
Fortunately, the patient achieved a full neurological recovery within 48 hours. This rapid improvement occurred after the cessation of the drug and intensive supportive care. Nevertheless, the case serves as a stark warning. Clinicians must remain vigilant regarding unconventional exposures. Furthermore, they should actively counsel patients about the hazards of non-evidence-based treatments. Misinformation online often omits the narrow therapeutic index of such medications in off-label settings.
Digital platforms frequently promote ivermectin as an alternative cancer therapy despite a lack of human clinical trials. While some in vitro studies show anticancer activity, the required concentrations are toxic to humans. Moreover, self-administration lacks the safety guardrails of professional oversight. Consequently, oncology teams should prioritize open communication about supplementary therapies. By doing so, they can identify potential risks before they escalate into emergencies.
No, the FDA and major oncology bodies have not approved ivermectin for cancer. Currently, no robust clinical evidence supports its efficacy in treating human malignancies.
Normally, the blood-brain barrier keeps ivermectin out using P-glycoprotein pumps. High doses saturate these pumps, allowing the drug to enter the brain and cause seizures or coma.
Management is primarily supportive. This includes airway protection, intravenous fluids, and controlling seizures with benzodiazepines. Clinicians should also contact a poison control center for guidance.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Saperstein Y et al. Life-threatening neurotoxicity following off-label ivermectin use in metastatic breast cancer: a case report. Postgrad Med. 2026 May 22. doi: 10.1080/00325481.2026.2672183. PMID: 42170801.
U.S. Food and Drug Administration. Why You Should Not Use Ivermectin to Treat or Prevent COVID-19. FDA Consumer Updates. 2023.
American Cancer Society. Ivermectin and Cancer: Exploring the Evidence and Risks. American Cancer Society Resources. 2026.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A case of life-threatening neurotoxicity in a breast cancer patient highlights the dangers of off-label ivermectin use and the impact of online misinformati...
2 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
